Literature DB >> 11901935

High-grade dysplasia in Barrett's esophagus. The case for esophagectomy.

Jean-Marie Collard1.   

Abstract

The main principles for optimal management of HGD arising in Barrett's esophagus are that unequivocal diagnosis of HGD is a prerequisite for making the decision of any kind of treatment. HGD must be resected because of the presence of neoplastic cells in the lamina propria in 40% of patients. No reliable endoscopic or endosonographic feature exists that allows accurate prediction of the existence of neoplastic cells within the lamina propria of a patient having HGD in endoscopic biopsy material. Prompt decision to remove an HGD lesion as soon as unequivocal histologic diagnosis has been settled prevents the development of extraesophageal neoplastic spread. Esophagectomy is preferable to endoscopic mucosal excision because approximately 20% of patients who have HGD in preoperative biopsy material carry neoplastic cells beyond the muscularis mucosae. Esophagectomy can be limited to the removal of the esophageal tube without extended lymphadenectomy because 96% of patients who have HGD in endoscopic biopsy samples have a neoplastic process confined to the esophageal wall. Esophageal resection must encompass all the Barrett's area because of the risk for the further development of a second cancer in the metaplastic remnant. Vagus-sparing esophagectomy with colon interposition or elevation of the antrally innervated stomach up to the neck is preferable to conventional esophagectomy with gastric pull up because the former procedure maintains gastric function intact, whereas the latter exposes patients to the risk for the long-term development of reflux esophagitis and even of metaplastic transformation of the proximal esophageal remnant. Subtle details in the understanding of a given patient's clinical course may be critical for making the decision of the most relevant mode of therapy; therefore, patients who have HGD should be treated in dedicated centers, the experience of which offers the best chances of uneventful recovery if the surgical option is retained.

Entities:  

Mesh:

Year:  2002        PMID: 11901935     DOI: 10.1016/s1052-3359(03)00067-x

Source DB:  PubMed          Journal:  Chest Surg Clin N Am        ISSN: 1052-3359


  14 in total

Review 1.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Endoscopic management of Barrett's esophagus: advances in endoscopic techniques.

Authors:  Ali Azarm; Ismet Lukolic; Meenal Shukla; Ronald Concha-Parra; Frank Gress
Journal:  Dig Dis Sci       Date:  2012-07-04       Impact factor: 3.199

3.  Minimally invasive esophagectomy for Barrett's with high-grade dysplasia and early adenocarcinoma of the esophagus.

Authors:  Arjun Pennathur; Omar Awais; James D Luketich
Journal:  J Gastrointest Surg       Date:  2010-04-01       Impact factor: 3.452

Review 4.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

5.  A novel esophageal-preserving approach to treat high-grade dysplasia and superficial adenocarcinoma in the presence of chronic gastroesophageal reflux disease.

Authors:  Toshitaka Hoppo; Stephen F Badylak; Blair A Jobe
Journal:  World J Surg       Date:  2012-10       Impact factor: 3.352

6.  Endoscopic mucosal resection versus esophagectomy for intramucosal adenocarcinoma in the setting of barrett's esophagus.

Authors:  Chao Li; Denise Tami Yamashita; Jeffrey David Hawel; Drew Bethune; Harry Henteleff; James Ellsmere
Journal:  Surg Endosc       Date:  2017-03-24       Impact factor: 4.584

7.  How radical should surgery be for early esophageal cancer?

Authors:  Dean Bogoevski; Maximilian Bockhorn; Alexandra Koenig; Matthias Reeh; Katharina von Loga; Guido Sauter; Thomas Rösch; Jakob R Izbicki
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

8.  Esophagus and regenerative medicine.

Authors:  Ricardo Londono; Blair A Jobe; Toshitaka Hoppo; Stephen F Badylak
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 9.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

Review 10.  Approach to early Barrett's cancer.

Authors:  Hubert J Stein; Marcus Feith; Burkhard H A von Rahden; J Rüdiger Siewert; Burkhard A H v Rahden
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.